109 related articles for article (PubMed ID: 11391824)
1. Cost-effectiveness of monolayers and human papillomavirus testing compared to that of conventional Papanicolaou smears for cervical cancer screening: protocol of the study of the French Society of Clinical Cytology.
Cochand-Priollet B; Le Galès C; de Cremoux P; Molinié V; Sastre-Garau X; Vacher-Lavenu MC; Vielh P; Coste J;
Diagn Cytopathol; 2001 Jun; 24(6):412-20. PubMed ID: 11391824
[TBL] [Abstract][Full Text] [Related]
2. A decade has passed...the Pap smear and cervical cancer.
Linder J
Am J Clin Pathol; 1997 Nov; 108(5):492-8. PubMed ID: 9353086
[No Abstract] [Full Text] [Related]
3. HPV for cervical cancer screening: is the era of the molecular pap smear upon us?
Stoler MH
J Histochem Cytochem; 2001 Sep; 49(9):1197-8. PubMed ID: 11511693
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of liquid-based cytology with or without hybrid-capture II HPV test compared with conventional Pap smears: a study by the French Society of Clinical Cytology.
Cochand-Priollet B; Cartier I; de Cremoux P; Le Galès C; Ziol M; Molinié V; Petitjean A; Dosda A; Merea E; Biaggi A; Gouget I; Arkwright S; Vacher-Lavenu MC; Vielh P; Coste J
Diagn Cytopathol; 2005 Nov; 33(5):338-43. PubMed ID: 16240398
[TBL] [Abstract][Full Text] [Related]
5. Benefits and costs of using HPV testing to screen for cervical cancer.
Mandelblatt JS; Lawrence WF; Womack SM; Jacobson D; Yi B; Hwang YT; Gold K; Barter J; Shah K
JAMA; 2002 May; 287(18):2372-81. PubMed ID: 11988058
[TBL] [Abstract][Full Text] [Related]
6. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?
Saraiya M; Berkowitz Z; Yabroff KR; Wideroff L; Kobrin S; Benard V
Arch Intern Med; 2010 Jun; 170(11):977-85. PubMed ID: 20548011
[TBL] [Abstract][Full Text] [Related]
7. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries.
Mandelblatt JS; Lawrence WF; Gaffikin L; Limpahayom KK; Lumbiganon P; Warakamin S; King J; Yi B; Ringers P; Blumenthal PD
J Natl Cancer Inst; 2002 Oct; 94(19):1469-83. PubMed ID: 12359856
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive testing for cervical cancer in low resource settings with visual inspection, HPV, and the Pap smear.
Blumenthal PD; Gaffikin L; Chirenje ZM; McGrath J; Womack S; Shah K
Int J Gynaecol Obstet; 2001 Jan; 72(1):47-53. PubMed ID: 11146077
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus.
Goldie SJ; Freedberg KA; Weinstein MC; Wright TC; Kuntz KM
Am J Med; 2001 Aug; 111(2):140-9. PubMed ID: 11498068
[TBL] [Abstract][Full Text] [Related]
10. Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness.
van Ballegooijen M; van den Akker-van Marle ME; Warmerdam PG; Meijer CJ; Walboomers JM; Habbema JD
Br J Cancer; 1997; 76(5):651-7. PubMed ID: 9303366
[TBL] [Abstract][Full Text] [Related]
11. Efficiency of the hybrid capture 2 HPV DNA test in cervical cancer screening. A study by the French Society of Clinical Cytology.
de Cremoux P; Coste J; Sastre-Garau X; Thioux M; Bouillac C; Labbé S; Cartier I; Ziol M; Dosda A; Le Galès C; Molinié V; Vacher-Lavenu MC; Cochand-Priollet B; Vielh P; Magdelénat H;
Am J Clin Pathol; 2003 Oct; 120(4):492-9. PubMed ID: 14560561
[TBL] [Abstract][Full Text] [Related]
12. Cost of screening for cancerous and precancerous lesions of the cervix.
Méréa E; Le Galès C; Cochand-Priollet B; Cartier I; de Crémoux P; Vacher-Lavenu MC; Vielh P; Coste J
Diagn Cytopathol; 2002 Oct; 27(4):251-7. PubMed ID: 12357505
[TBL] [Abstract][Full Text] [Related]
13. Liquid-based Papanicolaou smears without a transformation zone component: should clinicians worry?
Baer A; Kiviat NB; Kulasingam S; Mao C; Kuypers J; Koutsky LA
Obstet Gynecol; 2002 Jun; 99(6):1053-9. PubMed ID: 12052599
[TBL] [Abstract][Full Text] [Related]
14. Testing for human papillomavirus in women with abnormal pap smear results.
McCaffery KJ; Waller J; Forrest S; Wardle J
JAMA; 2002 Sep; 288(11):1350; author reply 1351-2. PubMed ID: 12234219
[No Abstract] [Full Text] [Related]
15. Laboratory implementation of human papillomavirus testing.
Bolick DR; Bolick RE; Coates F; Daniels CM; Juretich MB; Lin KK; Piper BL; Cummings L; Rosenfeld MJ; Spangler FL; Staley BE; Willmore BE; Willmore D
Arch Pathol Lab Med; 2003 Aug; 127(8):984-90. PubMed ID: 12873171
[TBL] [Abstract][Full Text] [Related]
16. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
Kim JJ; Burger EA; Sy S; Campos NG
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
[TBL] [Abstract][Full Text] [Related]
17. Cost of screening and treatment of cervical dyskaryosis in Germany.
Petry KU; Breugelmans JG; Bénard S; Lamure E; Littlewood KJ; Hillemanns P
Eur J Gynaecol Oncol; 2008; 29(4):345-9. PubMed ID: 18714567
[TBL] [Abstract][Full Text] [Related]
18. A model to evaluate the costs and clinical effectiveness of human papilloma virus screening compared with annual papanicolaou cytology in Germany.
Petry KU; Barth C; Wasem J; Neumann A
Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():132-139. PubMed ID: 28363186
[TBL] [Abstract][Full Text] [Related]
19. Chapter 13: Primary screening of cervical cancer with human papillomavirus tests.
Franco EL
J Natl Cancer Inst Monogr; 2003; (31):89-96. PubMed ID: 12807951
[TBL] [Abstract][Full Text] [Related]
20. Comparison of single-, double- and triple-combined testing, including Pap test, HPV DNA test and cervicography, as screening methods for the detection of uterine cervical cancer.
Kim JH; Kim IW; Kim YW; Park DC; Kim YW; Lee KH; Ahn TG; Han SJ; Ahn WS
Oncol Rep; 2013 Apr; 29(4):1645-51. PubMed ID: 23443346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
